Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 80.00p 78.00p 82.00p 80.00p 80.00p 80.00p 128.00 07:54:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.2 -5.6 -6.9 - 54.70

Avacta (AVCT) Latest News

More Avacta News
Avacta Takeover Rumours

Avacta (AVCT) Share Charts

1 Year Avacta Chart

1 Year Avacta Chart

1 Month Avacta Chart

1 Month Avacta Chart

Intraday Avacta Chart

Intraday Avacta Chart

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07/12/2016 09:29:2080.4043.22O
07/12/2016 08:43:3880.4012499.70O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
07/12/2016
08:20
Avacta Daily Update: Avacta is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 80p.
Avacta has a 4 week average price of 87.03p and a 12 week average price of 91.35p.
The 1 year high share price is 134.50p while the 1 year low share price is currently 79p.
There are currently 68,372,990 shares in issue and the average daily traded volume is 25,011 shares. The market capitalisation of Avacta is £54,698,392.
04/12/2016
09:27
wan: I note we now have the reason for the recent drop in the share price, in the form of a relatively large sell trade at 75p. I don't talk about the share price very often, but to perhaps put some perspective across regarding Avacta's share price performance, emerging U.S. biotech firms are down 39 percent this year and their European counterparts are down by 27 percent (and I appreciate that that probable doesn't make anyone feel any better). The main reason driving this under-performance, relative to the wider equity markets, is that drug pricing is weighing on investors minds and it has shifted sentiment. However, with large pharma showing strong interest in preclinical assets, it has been a good year for some companies with early stage assets to sell. Indeed, news elsewhere shows that large pharma is also very interested in alternatives to antibodies and it also continues to demonstrate their strong interest in preclinical assets - Better than ADCs? AstraZeneca bids for Bicyclic Peptides AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Peptides tend to be unpopular because they’re usually less specific than antibodies, although Amcure in Germany is also relying on them to treat cancer. Although the bicyclic peptide technology hasn’t proved itself worthy in the clinic yet, AstraZeneca seems to be attracted by the myriad advantages it offers. For Bicycle Therapeutics, this agreement means an expansion into new disease areas, which were mostly restricted to oncology so far. Full story - http://labiotech.eu/bicycle-therapeutics-astrazeneca/ The AstraZeneca deal with Bicycle is interesting in terms of the development stage of Bicycle. It is also perhaps more than interesting in terms of it being about an alternative to antibodies, which we know are expensive to produce (not to mention other issues). So this brings me back to drug pricing, and it is interesting that if a peptide works in a particular application then it could be attractive because it is easy to produce and subsequently much cheaper than antibodies. It will thus be interesting to see if acquiring or partnering assets that can ultimately reduce the cost of drugs becomes a trend. If so, then Avacta could be in an even better place than some are currently assuming. My research indicates that Affimers, being proteins, have larger interaction areas, have a greater range of conformations and higher affinities than peptides, hence the range of collaborations to date. So, while Bicycle's offering has clearly caught attention (another example of British success....well done!), it's not difficult to imagine that Affimers are attracting interest beyond the already declared interest coming from affinity separation, immunoassays and lateral flow diagnostics players. I appreciate though that some investors are only interested in substance i.e. something tangible and meaningful in terms of cash, as opposed to promises. But Avacta has attracted some very interesting and talented people (including collaborations), and such individuals don't usually align themselves to technologies or small companies without very good reason. Whilst some on here are inclined to describe Avacta as a failure waiting to happen, I am far more inclined to describe Avacta as another British success waiting to happen! We should champion British companies, especially ones that could also make a significant difference to peoples lives. Staying with British; I note that whilst I was away recently a sizeable UK focused fund is being created - Battle Against Cancer joins Wellcome to be £1bn champion Battle Against Cancer Investment Trust plans to team up with Wellcome Trust and become national champion in healthcare research The £483 million company today announced a big change in direction, unveiling plans to deepen its involvement in cancer research and biotechnology investment. It will potentially more than double in size to £1 billion and will gradually wind down its investments in alternative funds. ‘The same logic has given rise to this transaction, which will create a national champion of life science investing and accelerate the achievement of our aim: to win the battle against cancer and to create great returns for our investors at the same time.’ ‘This represents a major change in strategy for Bacit,’ said Numis analyst Ewan Lovett-Turner. ‘The tie-up with Wellcome Trust is an interesting development that looks set to create a sizeable listed company to support investment in UK life sciences. Full story - http://citywire.co.uk/money/battle-against-cancer-joins-wellcome-to-be-1bn-champion/a966356 And the following also stood out - £226 million UK investment in cancer research announced 1st December Cancer Research UK has announced the largest investment to date into its network of Centres across the UK. £190 million has been committed to 13 Cancer Research UK Centres over the next five years. “I’m particularly pleased that our international panel of experts, which renewed these Centres, stated repeatedly their view that there is no other network like this, of this quality, anywhere else in the world. “This is an exciting time for cancer research. Emerging treatments like immunotherapy are radically changing the field, we are increasingly able to tailor more treatments to individual patients, and advances in technology mean we can collect and share more research data than ever before. Full story - http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-12-01-ps226-million-uk-investment-in-cancer-research-announced
01/12/2016
10:32
dec2000: Clearly the market knows well in advance (24 hours) of us "normal shareholders" about RNS messages etc. However the drop in share price does not seem to have any fundamental support or reason. As I mentioned yesterday the drop in share price does not even seem to be linked to any significant share sale. The strategic update just released confirms everything we know about the company. There are no surprises. I e mailed Alastair Smith and whilst he cannot comment on share movements specifically, he expressed his "frustration" at yesterday's sudden movement and confirmed the steady progress of the company. Overall I believe the best conclusion is that this is an attempt to manipulate the share price (which often happens for small companies) and the right response is to sit tight and even use it as a buying opportunity
30/11/2016
18:41
dec2000: Yet Finncap yesterday placed a value on AVACTA of 200p in 12 months! Avacta Group PLC (LON:AVCT) Issued With ‘CorporateR17; Rating At FinnCap By Warren Smith / in UK Broker Ratings / on Wednesday, 30 Nov 2016 02:02 PM / 0 Comments Following an update released by analysts at finnCap on Tuesday the broker has now set a ‘CorporateR17; rating on shares of Avacta Group PLC (LON:AVCT) with a price target of 200. On Tuesday finnCap reiterated its target for shares of Avacta Group PLC as ‘CorporateR17; recommending a target price of 200 for investors; potentially meaning there is an increase of 129.75% from Avacta Group PLC’s share price of 87.05. Avacta Group PLC has 68,287,000 shares currently held by shareholders which currently trade around the 87.05 mark which totals Avacta Group PLC’s market capitalisation to 59.44M GBP. 12 Month Share Chart For Avacta Group PLC LON:AVCT In the duration of 12 months Avacta Group PLC’s share price has increased by 0% to 87.05 from 0.00. The business has a 50 day moving average of 89.99 and a 200 day moving average of 95.94 whilst the 52 week high shares of Avacta Group PLC have reached is 134.5 and the 52 week low is 83.02. Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company’s segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company’s in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and develoPment
30/11/2016
12:38
dec2000: if you look at the share trades it seems to have continued as normal then the share price fell a few p even though only a small number of trades was going through and then a sell order came through for 30000.. though the share price was dropping by then.. then subsequent partial rebound... either someone knows something we don't eg failure to sign a contract or even a hiccup with the Moderna deal or else its just a random fluctuation... no news on web site
13/11/2016
01:18
lantanatony: Mr angry Dec2000 has got it right. The share price will remain low until the Avacta Board does a deal that the market likes not just bits of information about jam tomorrow. The market knows what it wants and until then let's not expect too much.
12/11/2016
08:57
dec2000: I think it is about timing and the requirement of evidence over hope. On the therapeutic side, we have only evidence in one of six therapeutic programmes, and even then , although there have been encouraging preliminary results in the in-house PDL1 immuno oncology programme, we do not know a lot.. Yes we have been told there was significant anti tumour activity but we do not know how significant! The first real results in an efficacy study in man are perhaps 3 years away... In all six programmes. On the Rx Dx side all we know is that there are perhaps a dozen companies evaluating Affimers for various uses, whether as diagnostics or affinity separations or whatever. But again looking at the Avacta presentation, they do not foresee signing deals until some time in 2017 with revenue coming perhaps in 2018. The latest Hardman forward view on revenue would also support that kind of timescale. So whereas I am a huge fan of the company, I think it is only realistic to assume revenue and hence share price growth is some time away. And I note in my reading one of the best investors of all time when he ran the Magellan Fund, was quoted as saying one is better to invest in these small companies at stage 2 when growth is already apparent rather than at the beginning before growth has started!
07/10/2016
19:30
lantanatony: Wan and others The share price continues to fall. The Boad needs to bring some revenue.
01/10/2016
07:34
wan: Frustration generally comes to the fore when the backdrop is a drifting/falling share price, and I am not immune to that! However, I have not lost patience either. Currently the market appears more inclined to allow for a negative outlook (in one form or another). And to some degree it's not hard to fathom why, given that the attributes of Affimers (speed of development) are sitting somewhat conversely with the time taken to conclude deals, or actually commence revenue generation from existing partnerships, and this is possibly providing for an uncertain backdrop, in spite of the positive news flow, positive Avacta commentary and indeed other evidence suggesting the future for Affimers is indeed very bright. We know that Avacta are in various negotiations, but envariably these will be very complex and are thus taking longer to conclude than perhaps some were expecting, but what we don't want is a deal that undermines the true value, or importantly restricts the application base or limits other deal prospects. It's perhaps worth recalling that Avacta's new infrastructure (as previously discussed in post 817) is an important aspect in enabling additional therapeutic partnerships to be established. From the last FY results - "The progress made during the past year helped secure the Company's first substantial therapeutic partnership with Moderna Therapeutics and allowed the Company to raise GBP21m on 3 August to support in-house drug development plans as well as put the infrastructure in place to allow additional therapeutic partnerships to be established." The new infrastructure has only recently been established and allows for operations at both Avacta's sites to expand to meet increasing commercial demands, so with these elements now in place we should be at least a step closer to establishing further therapuetic partnerships. Therapuetics aside, I am still very confident that we will see "commercial" deals in the reagents/diagnostic and affinity purification space. However, at the same time I also appreciate some of the frustration in how long these are taking to conclude......but I would guess (and hope) that we are much closer to such deals than when last reported.
28/9/2016
10:28
lantanatony: Wan,I know you are trying to be helpful and I am impressed with your grasp of the subject. However,the share price continues to fall and I still believe it will until we see some revenue attached deals from substantial Bio-Phama companies. Like you I feel Avacta will make but I could be a while. Meanwhile,its up to the Avacta Board to add shareholder value. However,this impressive Board needs to do more to support the share price.Otherwise Henderson and others will lose patience. They invested at around 1.20 and must be a little disappointed ?
22/9/2016
12:24
lantanatony: Let's hope you are right, but the Avacta share price was around 1.50 not long ago. Also Henderson seem to be a seller.Do they know something we don't? We need a substantial deal with revenue attached. Meanwhile,I feel we will just see the share price fade.
Avacta share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161208 04:04:29